SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · CRM

Salesforce Delivers Record Second Quarter Fiscal 2027 Results

Salesforce, Inc. · Filed · SEC Form 8-K, Item 2.02

Salesforce, Inc. company page Original on SEC.gov ↗

Revenue $10.8 billion +12% vs a year ago
EPS $4.29 +119% vs a year ago
Guidance raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue grew 12% year on year to $10.8 billion, and EPS increased 119% to $4.29. Sales and earnings both ahead of a year ago is generally the cleaner kind of result. The company lifted its guidance, which is usually read as management's view of coming periods improving.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$10.8 billion +12% vs a year ago

…Subscription and support revenue of $10.8 billion, up 12% Y/Y and 11% in CC, including $440 million Informatica…
EPS

$4.29 +119% vs a year ago

…GAAP diluted net income per share of $4.29, up 119% Y/Y and non-GAAP diluted net income per share of $5.90, up 103% Y/Y…
Guidance

Guidance raised

…Delivers Record Second Quarter Fiscal 2027 Results cRPO growth accelerates to 14% Y/Y CC; Raises FY27 revenue guidance by $200M, $300M in CC.…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.